Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Bioequivalence of Two Subcutaneous Ocrevus Formulations in Multiple Sclerosis
2024-517980-22-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Primary endpoints: AUC0-12W of ocrelizumab and Cmax of ocrelizumab. Planned start Dec 2025; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2024-517980-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517980-22-00.